SCANCELL HLDGS ORD 0.1P (LSE:SCLP)

30.500
Today's low: 31.000
Sell SCLP
33.000
Today's high: 32.300
Buy SCLP
Last trade:
31.750
Change:
 0.250 (0.79%)
Volume:
31,937
Delayed price:
16:35:21
SETSqx
GBX

SCANCELL HLDGS ORD 0.1P (SCLP.L, LSE, LSE:SCLP)

SCLP Share Performance More

Technical Insight

Login or Register to access technical insights.

Latest newsMore

Director/PDMR Shareholding

RNS Number : 9715J Scancell Holdings Plc 19 June 2014 19 June 2014 Scancell Holdings Plc (Scancell or the Company) Grant of Options to Director Scancell, the developer of novel immunotherapies for the treatment of cancer, announces that further to the recent update of results from its on-going Phase 12 clinical trial on 2 June 2014, options over 500,000 ordinary shares (the Options) have been granted on 18 June 2014 to Dr Sally Adams, ...

Scancell Holdings - SCIB1 Phase 1/2 clinical trial results presented at ASCO and DNA ImmunoBody patent granted in United States

DNA ImmunoBody Patent Granted in United States

RNS Number : 9796I Scancell Holdings Plc 06 June 2014 06 June 2014 Scancell Holdings Plc DNA ImmunoBody Patent Granted in United States Scancell Holdings plc (Scancell or the Company), the developer of novel immunotherapies for the treatment of cancer, is pleased to announce that a patent for its DNA ImmunoBody technology has been granted in the United States. The patent, number 8,742,088, has been granted by The United States ...

Scancell updates on Phase 1/2 trial of SCIB1 in melanoma

Scancell Holdings confirms further encouraging results from its on-going Phase 12 clinical trial in patients with Stage IIIIV melanoma treated with the SCIB1 ImmunoBody. The updated data was presented in a poster at the 2014 American Society of Clinical Oncology (ASCO) meeting in Chicago on Sunday 1 June 2014.

Update on Phase 1/2 trial of SCIB1 in melanoma

RNS Number : 5562I Scancell Holdings Plc 02 June 2014 2 June 2014 Scancell Holdings Plc Update on Phase 12 clinical trial of SCIB1 in Stage IIIIV melanoma Further evidence of tumour reduction and disease control, enhanced immune responses and highly encouraging survival times Scancell Holdings plc (Scancell or the Company), the developer of novel immunotherapies for the treatment of cancer, is pleased to announce further encouraging ...

Presents latest SCIB1 data at ASCO

RNS Number : 1834H Scancell Holdings Plc 15 May 2014 15 May 2014 Scancell Holdings Plc (Scancell or the Company) Scancell to present latest SCIB1 data at ASCO Annual Meeting Scancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, today announces that the latest data from the ongoing Phase 12 clinical trial of SCIB1 ImmunoBody (SCIB1) in patients with Stage IIIIV melanoma will be presented ...